Key result
Perioperative antithrombotic management in head and neck surgery requires balancing thromboembolism and hemorrhage risks, with limited data from randomized controlled trials to guide decisions.
Perioperative antithrombotic management in head and neck surgery requires carefully balancing thromboembolic and bleeding risks, particularly given the potential for airway compromise.
Requires case-by-case antithrombotic decisions to balance dual risks in head and neck surgery; leaves open the need for RCTs to guide practice.
Head and neck surgeons are commonly faced with surgical patients who have underlying medical problems requiring antithrombotic therapy. It is difficult to achieve a balance between minimizing the risk of thromboembolism and hemorrhage in the perioperative period. Data from randomized, controlled trials are limited, and procedure-specific bleed rates are also difficult to pinpoint. The decision is made more difficult when patients with moderate-to-high risk for thromboembolic events undergo procedures that are high risk for bleeding. This is true for many head and neck oncologic surgeries. Furthermore, although elective procedures may be delayed for optimization of antithrombotic medication, emergent procedures cannot. Head and neck surgery often represents the most challenging of all these circumstances, given the potential risk of airway compromise from bleeding after head and neck surgery.
No takes yet. Share an insight, caveat, or question.
Meyer et al. (2017) conducted a review in Head and neck surgery requiring antithrombotic therapy. Perioperative antithrombotic management was evaluated. Perioperative antithrombotic management in head and neck surgery requires balancing thromboembolism and hemorrhage risks, with limited data from randomized controlled trials to guide decisions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: